Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing and sequence of COVID-19 and influenza vaccination
NL-OMON51262Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tozinameran, Ad26.COV2.S and influenza vaccine in coronavirus disease 2019 (COVID-19) and influenza, sponsored by Radboud University Medical Center. Primary endpoint: Geometric mean titers of spike-specific IgG. Started Oct 2021; status: active, not recruiting.
02
Drugs
tozinameranAd26.COV2.Sinfluenza vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NL-OMON51262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51262.